logo-loader
viewMotif Bio PLC

Motif Bio has 'considerable potential upside', according to Shard

microscope_554cc4e9485a9.jpg

Newly-floated Motif Bio (LON:MFTB) has ‘considerable potential upside’, according to the number crunchers Shard Capital.

The company is developing a best-in-class antibiotic called iclaprim that it is hoped will be able to target resistant strains of bacteria.

Not just that, in iclaprim it has a drug candidate that is ready to go into the final phase of clinical trials and could be out in the market in 18 months.

Shard estimates Motif will probably need to spend around £20mln to carry out these studies, which might mean tapping investors. But more likely it will find an industry partner to foot the bill.

Motif’s current market capitalisation is just £21.2mln, which Shard points out points values the business at a fraction of its closest benchmark company, the US firm Paratek, which is worth £310mln.

“This strongly suggests that there is considerable upside potential in Motif,” said analyst Mark Brewer.

LON:MTFB/MotifBio/">Click here to read the reoport in full. It can be found under the Presentations and Company Media tab.

Quick facts: Motif Bio PLC

Price: 0.55 GBX

AIM:MTFB
Market: AIM
Market Cap: £2.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Motif Bio announces US FDA approval deadline for its antibiotic drug

Motif Bio (LON:MTFB, NASDAQ: MTFB) CEO Graham Lumsden tells Proactive Investors the US FDA has begun the process of assessing whether the company’s next-generation antibiotic should be allowed to go on sale in the US. Motif's drug iclaprim has been granted a priority review by the...

on 08/15/2018

2 min read